ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.35 -1.35%

-$0.02 today

Market cap
$189.89M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.09M

Average 1.68M

Returns on capital

ADC Therapeutics S.A. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

76.7%

avg -33.1%

ROIC

-42.3%

avg -50.7%

ROA

-44.1%

avg -47.7%

Analysis

ROE is currently the strongest return metric at 76.7% versus its period average of -33.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Ameet Mallik

Chief Executive Officer & DirectorUSD 1.41M532.12M1.67%

Mohamed Zaki

Chief Medical OfficerUSD 1.15M61896.32K0.70%

Jose I. Carmona

Chief Financial OfficerUSD 860.6K54——

David S. Ege

Chief Technical Officer—52——

Peter J. Graham

Secretary and Chief Legal & Compliance Officer—59841.64K0.66%

Kimberly Pope

Senior Vice President & Chief People Officer—59——

Kristen Harrington-Smith

Chief Commercial Officer—53——

Lisa Michelle Kallebo

Corporate Controller & Chief Accounting Officer——128.22K0.10%

Marcy Graham

Investor Relations Officer—59——

Nicole Riley

Head of Investor Relations & Corporate Communications————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

6

$19.64M

Net Transaction Value

−$19.64M

Net selling

Most Active

Redmile Group, LLC

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 2, 26

Redmile Group, LLC

Direct

Sell$8.3M
Apr 2, 26

Redmile Group, LLC

Indirect

Sell$8.6M
Apr 1, 26

Redmile Group, LLC

Direct

Sell$617.4K
Apr 1, 26

Redmile Group, LLC

Indirect

Sell$643K
Mar 31, 26

Redmile Group, LLC

Direct

Sell$706.9K
Mar 31, 26

Redmile Group, LLC

Indirect

Sell$736.3K

Summary

Insiders reported 0 buys worth $0.00 and 6 sells worth $19.64M over the last 12 months. That adds up to net selling of $19.64M. Redmile Group, LLC was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-27.1%
+30.5% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -27.1% over three years. Forward estimates point to Revenue at +30.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does ADC Therapeutics S.A. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ADCT's management, answered from reported figures.

Who manages ADCT?

ADC Therapeutics S.A. (ADCT) lists 10 active executives. The top listed executive is Ameet Mallik, Chief Executive Officer & Director.

Are ADCT insiders buying or selling?

Recent insider activity shows net selling of $7.12M.